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Introduction
The intent of this project is to develop an effective DC vaccine strategy for patients with breast cancer. While current DC vaccines are safe, their antitumor activity is limited (1) (2) (3) . This is foremost due to the presence of regulatory T cells (Tregs), which create an immunosuppressive environment in breast cancer patients (4) (5) (6) (7) (8) (9) (10) (11) . In addition, there is increasing evidence that effective solid tumor vaccines have to target cancer cells as well as their supporting stroma (12) (13) (14) (15) (16) (17) (18) (19) (20) . Therefore, we hypothesized that overcoming Treg mediated immune suppression and targeting the tumor stroma in addition to breast cancer cells may produce the desired increase in antitumor activity of DC vaccines for breast cancer.
In our previous study, we have demonstrated that silencing the zinc-finger A20 in DCs overcomes Tregmediated immunosuppression in tumor bearing mice using ovalbumin as a model antigen (21) . Since effective Treg depletion prior to vaccination has proven difficult, A20-silenced DC vaccine might represent an alternative strategy to overcome Treg-mediated immunosuppression. Thus in this project we proposed to develop an A20-silenced DC vaccine to activate breast cancer-and stroma-specific cytotoxic T lymphocytes (CTL), while concomitantly inhibiting Tregs. This novel vaccine targets the human epidermal growth factor receptor (HER)2 expressed on breast cancer cells and the fibroblast activating protein (FAP) expressed on the supporting tumor stroma.
In the first year of this award, recombinant lentiviral vector expressing shA20, FAP, and HER2 (Lv-shA20-FAP-HER2) was prepared and immunized to 4T1.2-neu tumor bearing mice. First, Lv-shA20-FAP-HER2 and control vectors (Lv-shA20-FAP, Lv-shA20-HER2, Lv-shGFP-FAP, Lv-shGFP-HER2, Lv-shGFP-FAP-HER2) were prepared and transduced to mice bone-marrow derived DCs. Then these DC vaccines were immunized to Balb/c mice. The results indicated that immunization of A20-silenced DC vaccine induced more robust T cell responses against FAP or HER2, compared to that of GFP-silenced DC vaccine. In addition, the immunization of DC-shA20-FAP-HER2 inhibited 4T1.2-neu growth more efficiently, compared to that of control vaccines.
In the second year of this award, we have proposed to evaluate these DC vaccines using HER2 transgenic mice. However pilot studies shown FAP-targeted DC vaccine had limited therapeutic effects on tumor-bearing HER2-transgenic mice and it takes too long time to raise sufficient amount HER2 transgenic mice for further mechanistic studies. Therefore, we have focused on the mechanistic studies in an alternative B16 tumor model. The central hypothesis of this study is that co-targeting tumor antigen and FAP would more efficiently induce antigen spreading, resulting in the elimination of antigen loss variants. The results indicated that the immunization of DC-shA20-FAP-TRP2 significantly induced activation of CTLs against other tumor antigens expressed by B16. Further, the immunization of DC-shA20-FAP-OVA significantly inhibited B16 (antigen loss variant of B16-OVA) growth in mice, suggesting that co-targeting cancer antigen and FAP represents an optimized vaccination strategy.
Characterization of genetically modified DC functions in vitro.
We transduced bone-marrow derived DCs from Balb/c mice with Lenti-shA20-HER2-FAP, or controls. Mouse bone marrow (BM)-derived DCs were prepared as described in our previous study (21) (22) (23) (24) . Briefly, mouse bone marrow was flushed from limbs, passed through a nylon mesh, and depleted of red cells with ammonium chloride. After extensive washing with RPMI-1640, cells were cultured with 2.5 ml of RPMI-1640 supplemented with 10% FBS, mGM-CSF/ml (20 ng/ml) and recombinant mouse IL-4 (20 ng/ml; PeproTech). On days 2 and 4 of culture, the supernatant was removed and replaced with fresh media containing 20 ng/ml of rmGM-CSF and 20 ng/ml of rmIL-4. All cultures were incubated at 37°C in 5% humidified CO 2 . Nonadherent granulocytes were removed after 48 hr of culture and fresh medium was added. After 7 days of culture, >80% of the cells expressed characteristic DC-specific markers as determined by FACS. Transduction of BM-derived DCs with these LV vectors routinely yielded 30-60% of cells (data not shown). A20 expression in Lv-shA20 transduced DC was downregulated by 80-90% in comparison to DCs transduced with the control vector (data not shown). FAP and HER2 expression of transduced BM-DCs was confirmed by RT-PCR. strategy was able to induce enhanced FAP-and HER2-specific T cell responses. Balb/C mice were immunized with DC vaccines or PBS, and the functional status of CD8 + and CD4 + T cells was then evaluated using interferon (IFN)-γ ELISPOT assays. We observed that mice immunized with A20-silenced DC vaccines had significantly higher frequencies of IFN-γ + CD8 + T (Fig. 2) and CD4 + T cells (Not shown), compared to those given DC-shGFP vaccines. These data demonstrate a critical role for A20 in control of the magnitude of FAPand HER2-specific T-cell responses.
Evaluation

DC-shA20-FAP-HER2 vaccination inhibits 4T1-neu progression.
We investigated whether DC-shA20-FAP-HER2 may induce more potent antistroma and anti-tumor immunity with the ability to control the growth of tumors. DC vaccines were immunized to the Balb.C mice followed by inoculation of 4T1.2-neu tumor in the fourth mammary fat pad in 7 days later (Fig. 3) . By targeting both FAP and HER2, one immunization of DC-shA20-FAP-HER2 completely prevent the progression of 4T1.2-neu tumor in 80 days. These results demonstrate the DC-shA20-FAP-HER2 has potent antitumor activity.
DC-shA20-FAP vaccine decreases immunosuppressive cells in the tumor.
We investigated whether DCshA20-FAP vaccination results in a decrease in suppressive cells in the tumors. While we are evaluating our vaccine using 4T1.2-neu mice model, we also used B16 mice model. Staining B16 tumors for CD11b identified a large population of infiltrating macrophages (Fig.4A) , which significantly decreased after vaccination of FAPtargeted DC vaccine. We observed that both the CD11b + Gr1 dim population and CD11b + Gr1 hi population were significantly decreased after vaccination of FAP-targeted DC vaccine from 41.38% to 26.44% and 4.37% to 2.48%, respectively. In addition, upregulation of CD80 expression on tumor infiltrating CD11c + population was observed in the recipients of FAP-targeted DC vaccine (Fig.4B) . Taken together, these data indicate that our FAP-targeted DC vaccine decreases immature DC and tumor-associated macrophages, supporting our hypothesis in Aim 1 that the A20-silenced FAP-targeted DC vaccine has the potential to reverse the suppressive tumor microenvironment.
DC-shA20-FAP vaccine enhances CD8 infiltration in the tumor. We also investigate whether DC-shA20-FAP vaccine enhance CD8 infiltration in B16 tumors. Staining for CD8 showed that there was a dramatic increase in CD8 + T cells within the tumor after DC-shA20-FAP vaccination. These changes were statistically significant and represented a 3-fold (7.72%:19.31%) change in CD8 + proportion in the tumor (Fig. 5) . These data support our hypothesis in Aim.1.C that A20-silenced FAPtargeted DC vaccine has the potential to enhance the infiltration and proliferation of tumor-specific T cells at the tumor site. Summary. The data described above demonstrated that DC-shA20-FAP-HER2 vaccine induce robust T cell responses against FAP or HER2, resulting enhanced antitumor effect. Functional characterization of lentiviral vectors encoding shA20, FAP and TRP2. To evaluate the vaccine in a B16 model, we first constructed 4 lentiviral vectors encoding shA20 and FAP (Lv-shA20-FAP), shA20 and TRP2 (Lv-shA20-TRP2), shA20, FAP and TRP2 (Lv-shA20-FAP-TRP2), or a control shRNA, FAP, TRP2 (LvshCo-FAP-TRP2) (Fig. 6A) . Transgene expression, and silencing of A20 was confirmed by RT-PCR in bonemarrow derived DCs transduced with VSV-G pseudotyped lentiviral vectors (Fig. 6B,C) . To demonstrate that Lv-transduced DCs induce FAP-and TRP2-specific T-cell responses, mice were vaccinated with 1x10 6 DC-shA20-FAP, DC-shA20-TRP2, DC-shA20-FAP-TRP2, or DC-shCo-FAP-TRP2. Fourteen days post vaccination CD4-and CD8-positive splenocytes were isolated and the presence of FAPand TRP2-specific T cells was determined by IFN-γ Elispot assays. Mice vaccinated with A20-silenced DC vaccines induced significantly higher FAP-and TRP2-specific CD4-and CD8-positive T-cell responses (p<0.05) than mice vaccinated with DC-shCo-FAP-TRP2, confirming our previous finding that silencing of A20 in DCs promotes the induction of robust CD4-and CD8-positive antigen-specific T-cell responses in vivo (Fig.  6D,E) . There was no significant difference (p>0.05) in the induction of FAP-or TRP2-specific T cells responses after vaccinating mice with DCs expressing individual (DC-shA20-FAP or DC-shA20-TRP2) or both antigens (DC-shA20-FAP-TRP2), indicating absence of antigenic competition when both antigens are co-expressed.
DC-shA20-FAP-TRP2 vaccine has potent antitumor activity. The B16 melanoma model is ideal to evaluate if targeting FAP-positive tumor stroma enhances antitumor effects since B16 cells do not express FAP. We confirmed the induction of FAP expression within 5 days post B16 tumor implantation by RT-PCR (Fig. 7A) . Mice bearing 5 day-old B16 tumors were vaccinated with a single dose of the 1x106 DC-shA20-FAP, DCshA20-TRP2, DC-shA20-FAP-TRP2, or DC-shCo-FAP-TRP2 vaccine. All A20-silenced vaccines had antitumor activity, while non-A20 silenced DC vaccine had none (Fig. 7B) . There was no difference in the antitumor activity of DC-shA20-FAP and DC-shA20-TRP2 vaccines, indicating that T-cell responses against a stroma antigen alone can have significant antitumor effects (Fig. 7B) . Targeting FAP and TRP2 simultaneously with the DC-shA20-FAP-TRP2 vaccine resulted in the greatest antitumor activity (DC-shA20-TRP2 vs DC-shA20-FAP-TRP2, p<0.05; DC-shA20-FAP vs DC-shA20-FAP-TRP2, p<0.05). This resulted in a significant increase in survival of mice that received DC-shA20-FAP-TRP2 vaccine in comparison to the other vaccine groups (Fig.7C) . Fig. 8C) , mirroring the previously observed overall increase in the number of CD8-positive T cells within tumors.
Fig.7.: DC-shA20-FAP-TRP2 vaccine has potent antitumor activity. (A) RT-PCR for FAP and GAPDH of B16 cell line, and day 5 B16 tumors. (B,C) Mice were inoculated with B16 followed by immunization with 1x106 DCshA20-FAP (AF), DC-shA20-TRP2 (AT), DC-shA20-FAP-TRP2 (AFT), DC-shCo-FAP-TRP2 (ACT) or PBS on day 5 (n= 5 per group). (B) Cotargeting FAP and TRP2 with AFT resulted in the greatest antitumor response (AF vs AFT, p<0.05; AT vs AFT, p<0.05). (C) Kaplan-Meier survival curve (AF vs AFT, p<0.05; AT vs AFT, p<0.05).
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DC-shA20-FAP-TRP2 vaccine induces antigen spreading.
In the previous experiment we noticed that the DC-shA20-FAP vaccine induced TRP2-specific T-cell responses, suggestive of epitope spreading and the induction of antigen spreading. To further investigate this finding, B16 tumor-bearing mice were vaccinated on day 5 with DC-shA20-FAP, DC-shA20-TRP2, DC-shA20-FAP-TRP2, or PBS. After 3 weeks the frequency of T cells specific for the B16-associated tumor antigens tyrosinase-related protein 1 (TRP1), tyrosinase (Tyr), gp100, and melanoma-associated antigen recognized by T cells (MART1) among splenocytes and tumor infiltrating lymphocytes was determined. While all vaccines induced a significant increase of TRP1-, Tyr-, gp100-, and MART1-specific T cells in TILs in comparison to PBS-injected mice (Fig. 9A) , the frequency of melanoma-specific T cells was highest in DC-shA20-FAP-TRP2 vaccinated mice (p<0.05). Only the DCshA20-FAP-TRP2 vaccine induced systemic T-cell responses against TRP1, Tyr, gp100, and MART1 (Fig.9B) . These results indicate that targeting of the tumor stroma as well as the tumor enables the induction of antigen spreading. Antigen spreading results in enhanced antitumor activity. Having shown that the developed compound vaccines induced B16 antigen spreading we wanted to determine if these antigen-specific T cells have antitumor activity. Mice were inoculated with B16-OVA and B16 on their right or left flanks, and after 5 days vaccinated with DC-shA20-FAP, DC-shA20-OVA, DC-shA20-FAP-OVA, or PBS. DC-shA20-OVA vaccination only inhibited the growth of B16-OVA, while the DC-shA20-FAP vaccine inhibited B16 as well as B16-OVA tumor growth (Fig. 10A,B) . The DC-shA20-FAP-OVA vaccine had the greatest antitumor activity against both tumor cell lines (p<0.05; Fig. 10A,B) . This is consistent with our observation that co-targeting tumor antigen and FAP induces systemic T cells responses against tumor antigen not present in the vaccine (Fig.4B) . While DC-shA20-OVA vaccination did not result in an increase in overall survival, due to the antigen negative B16 tumors, DC-shA20-FAP or DC-shA20-FAP-OVA vaccination resulted in a significant increase in overall survival in comparison to DC-shA20-OVA (p<0.05; Fig 10C) . To further confirm the systemic induction of T cells specific for antigens not present in the vaccine, mice were injected with B16-OVA and vaccinated after 5 days with DC-shA20-FAP, DC-shA20-OVA, DC-shA20-FAP-OVA, or PBS. After 3 weeks splenocytes of vaccinated mice were isolated and restimulated for 5 days ex vivo before performing a cytotoxicity assay with B16-OVA and B16 cells as targets. Splenocytes harvested from DC-shA20-FAP or DC-shA20-FAP-OVA vaccinated mice showed significant killing of B16-OVA and B16 cells (Fig. 10D,E) , where as the DC-shA20-OVA vaccine primarily induced OVA-specific T-cell responses.
Taken together, our results demonstrate that a DC vaccine in which the antigen presenting attenuator A20 is inhibited, and that targets FAP-positive CAFs and the tumor antigen has potent antitumor effects, enables cross-presentation of tumor antigens by intratumoral APCs resulting in the broad-based induction of T cells specific for tumor antigens not included in the vaccine.
Conclusions
• Demonstrates critical role for A20 in regulating the extent of T cell responses against FAP and HER2
• Demonstrates critical role for co-targeting FAP and tumor antigen in eliminating antigen loss variants.
• Providing an effective approach for developing potent DC vaccine against breast cancer.
attenuator A20 in DCs renders DC resistant to tumor-mediated immunosuppression. In this study we constructed a new compound vaccine, which encodes an A20-specific Flow cytometric analysis. Flow cytometric analysis of DCs and T cells and were performed as previously described 18, 24 . Inguinal lymph nodes were dissociated and plated in complete RPMI with lentivirus-transduced DCs for an overnight stimulation at 37°C followed by intracellular staining. Stained cells were analyzed on a FACScalibur instrument (BD, Becton Dickinson, Mountain View, CA) using CellQuest software (BD) for all flow-cytometric analyses.
ELISPOT assays. ELISPOT assays of isolated T cells were performed as described previously described 18, 24 . spleens were dissociated and purified by using MACS CD4 (L3T4) or CD8 (Ly-2) 
MicroBeads (Miltenyi Biotec
)
RESULTS
Functional characterization of lentiviral vectors encoding shA20, FAP and TRP2
We constructed 4 lentiviral vectors encoding shA20 and FAP (Lv-shA20-FAP), shA20
and TRP2 (Lv-shA20-TRP2), shA20, FAP and TRP2 (Lv-shA20-FAP-TRP2), or a control shRNA, FAP, TRP2 (Lv-shCo-FAP-TRP2) (Fig. 1A) . Transgene expression, and silencing of A20 was confirmed by RT-PCR in bone-marrow derived DCs transduced with VSV-G pseudotyped lentiviral vectors (Fig. 1B,C) . (Fig. 1D,E) . There was no significant difference silenced DC vaccine had no antitumor activity where as all A20-silenced vaccines did ( Fig. 2A) . There was no difference between DC-shA20-FAP and DC-shA20-TRP2
vaccines, indicating that the induction of T-cell responses against a stroma antigen like FAP alone can be associated with significant antitumor effects ( Fig. 2A) . Targeting FAP and TRP2 simultaneously with the DC-shA20-FAP-TRP2 vaccine resulted in the greatest antitumor activity (DC-shA20-TRP2 vs DC-shA20-FAP-TRP2, p<0.05; DCshA20-FAP vs DC-shA20-FAP-TRP2, p<0.05). This finding was confirmed using a DCshA20-FAP-OVA vaccine in B16-OVA and EG7-OVA models (Supplemental Fig.   1A ,B).
DC-shA20-FAP-TRP2 vaccine increases FAP-and TRP2-specific CD8-positive T cells in tumors
To investigate the mechanisms of how the DC-shA20-FAP-TRP2 vaccine enhances antitumor effects, we first determined the frequency of CD4-and CD8-positive T cells in (Fig. 3A,B) . (Fig. 3C) , mirroring the previously observed overall increase in the number of CD8-positive T cells within tumors.
DC-shA20-FAP-TRP2 vaccine induces bystander T-cell responses by activating
APCs within tumors
In the previous experiment, the DC-shA20-FAP vaccine induced TRP2-specific T-cell responses (Fig. 3C) , suggestive of epitope spreading and the induction of bystander Tcell responses. To further investigate this finding, B16 tumor-bearing mice were vaccinated on day 5 with DC-shA20-FAP, DC-shA20-TRP2, DC-shA20-FAP-TRP2, or PBS. After 3 weeks the frequency of T cells specific for the B16-associated tumor antigens tyrosinase-related protein 1 (TRP1), tyrosinase (Tyr), gp100, and melanomaassociated antigen recognized by T cells (MART1) was determined in splenocytes as well as tumor infiltrating lymphocytes. Only the DC-shA20-FAP-TRP2 vaccine induced systemic T-cell responses against TRP1, Tyr, gp100, and MART1 (Fig.4 A) . While all vaccines induced a significant increase of TRP1-, Tyr-, gp100-, and MART1-specific T cells in TILs in comparison to PBS-injected mice (Fig. 4B) , the frequency of melanoma-11 specific T cells was highest in DC-shA20-FAP-TRP2 vaccinated mice (p<0.05). These results indicate that targeting of the tumor stroma as well as the tumor is necessary to induce potent bystander, tumors-specific T-cell responses.
To investigate the mechanisms of enhanced bystander T-cell induction we determined the expression of the costimulatory molecules CD80 and CD86 on F4/80-positive (monocytes/macrophages) and CD11c-positive (DCs) APCs within tumors, and their ability to cross present the B16-associated antigen gp100. DC-shA20-FAP, DC-shA20-TRP2, and DC-shA20-FAP-TRP2 vaccines induced the expression of CD80 and CD86
on intratumoral APCs in comparison to PBS-vaccinated mice (Fig 5A) . While monocytes/macrophages and DCs isolated form tumors of DC-shA20-FAP-TRP2 vaccinated mice had the highest level of CD80/CD86 expression, this difference did not reach statistical significance. To evaluate if monocytes/macrophages or DCs, isolated from tumors of DC-shA20-FAP, DC-shA20-TRP2, or DC-shA20-FAP-TRP2 vaccinated mice, were able to cross-present gp100 we performed IFN-γ ELISPOT assays using freshly isolated APCs from tumors and splenocytes from pmel17/gp100 TCR transgenic mice (gp100-specific TCR T cells) as effectors. Only APCs isolated from tumors of DCshA20-FAP-TRP2 vaccinated mice were able to activate gp100-specific T cells ( (Fig. 5C) , confirming that cotargeting of the tumor cells and CAFs is necessary for effective cross-presentation of tumor-derived antigens by intratumoral APCs.
Induced bystander T cells have antitumor activity
Having shown that the developed compound vaccines induced B16-specific, bystander (Fig. 6A,B) . The DC-shA20-FAP-OVA vaccine had the greatest antitumor activity against both cell lines (p<0.05; Fig. 6A,B ).
To further demonstrate the systemic induction of cytotoxic bystander T-cell responses in this model, mice were injected with B16-OVA and vaccinated after 5 days with DCshA20-FAP, DC-shA20-OVA, DC-shA20-FAP-OVA, or PBS. After 3 weeks splenocytes of vaccinated mice were isolated and restimulated for 5 days ex vivo before performing 13 a cytotoxicity assay with B16-OVA and B16 cells as targets. Splenocytes harvested from DC-shA20-FAP or DC-shA20-FAP-OVA vaccinated mice showed significant killing of B16-OVA and B16 cells (Fig. 6C,D) , where as the DC-shA20-OVA vaccine primarily induced OVA-specific T-cell responses.
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Our results demonstrate that a vaccine that inhibits the antigen presenting attenuator 
